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Background: The delivery of a simultaneous integrated boost to the intra-prostatic tumour nodule may improve
local control. The ability to deliver such treatments with hypofractionated SBRT was attempted using RapidArc
(Varian Medical systems, Palo Alto, CA) and Multiplan (Accuray inc, Sunnyvale, CA).
Materials and methods: 15 patients with dominant prostate nodules had RapidArc and Multiplan plans created
using a 5 mm isotropic margin, except 3 mm posteriorly, aiming to deliver 47.5 Gy in 5 fractions to the boost whilst
treating the whole prostate to 36.25 Gy in 5 fractions. An additional RapidArc plan was created using an 8 mm
isotropic margin, except 5 mm posteriorly, to account for lack of intrafraction tracking.
Results: Both RapidArc and Multiplan can produce clinically acceptable boost plans to a dose of 47.5 Gy in 5 fractions.
The mean rectal doses were lower for RapidArc plans (D50 13.2 Gy vs 15.5 Gy) but the number of missed constraints
was the same for both planning methods (11/75). When the margin was increased to 8 mm/5 mm for the RapidArc
plans to account for intrafraction motion, 37/75 constraints were missed.
Conclusions: RapidArc and Multiplan can produce clinically acceptable simultaneous integrated boost plans, but the
mean rectal D50 and D20 with RapidArc are lower. If the margins are increased to account for intrafraction motion, the
RapidArc plans exceed at least one dose constraint in 13/15 cases. Delivering a simultaneous boost with hypofractionation
appears feasible, but requires small margins needing intrafraction motion tracking.
Keywords: Stereotactic body radiotherapy, Prostate cancer, Focal boostIntroduction
Dose escalation is known to improve biochemical con-
trol in prostate cancer [1-4] however at conventional
fractionations, this is associated with an increase in tox-
icity [1-3]. Studies deriving the alpha-beta ratio for pros-
tate cancer from low-dose rate brachytherapy and
external beam treatments have suggested the alpha-beta
ratio is possibly as low as 1.5 Gy [5-7]. It is hypothesized
that we can exploit this unusual tumour characteristic to
permit radiobiological dose escalation without increasing
toxicity using fewer, larger doses of radiation (hypo-
fractionation). Studies of moderate hypofractionation (up
to 3.5 Gy per fraction) have shown toxicity which is, at
worst, equivalent to standard fractionation [8-10] and* Correspondence: alison.tree@rmh.nhs.uk
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reproduction in any medium, provided the orthere are some early suggestions of improved biochemical
control [9,10]. Further data is eagerly awaited. Stereotactic
body radiotherapy (SBRT) is an emerging technique for
treating localized prostate cancer using 4–5 doses of 7 Gy
or higher (36.25 Gy in 5 fractions is a commonly used
dose). Results from both retrospective and prospective
series show good biochemical outcomes in those with low
and intermediate risk disease [11-14], which serves to re-
affirm the concept of a low alpha/beta ratio for prostate
cancer. Almost all the literature on prostate SBRT delivers
these treatments on Cyberknife but there is increasing
interest in using conventional linacs to deliver SBRT.
Studies of patterns of failure following conventionally
fractionated external beam radiotherapy show that the
area responsible for local recurrence is the dominant
intraprostatic nodule in 89% [15] – 100% [16] of cases.
By dose escalating the dominant nodule we should. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Planning schema.
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in side effects seen with whole gland dose escalation.
SBRT using Cyberknife is capable of producing dose
distributions that are similar to those achieved with
HDR, with a rapid dose fall off and the ability to create
heterogeneous dose distributions within the prostate
[17]. The objective of this study is to achieve a heteroge-
neous dose distribution, with the high dose region
(47.5 Gy) targeted to the dominant intraprostatic nodule,
whilst maintaining a dose of 36.25 Gy to the whole pros-
tate. We compared the two methods of SBRT delivery
available to us at our institution – Cyberknife (using




This study was prospectively approved by the Royal
Marsden service evaluation committee. Fifteen patients
with intermediate or high risk prostate cancer, who had
received standard IMRT at our institution, and who had
a dominant prostate disease nodule (DPDN) on their
diagnostic MRI, were selected. All patients had standard
bladder filling protocol (300 mls at 45 minutes prior to
planning CT scan) and no routine bowel preparation
prior to the radiotherapy planning scan.
Volume definition
The diagnostic MRI scan was fused with the planning
CT scan. The DPDN was contoured jointly by the
oncologist and the radiologist using MRI (T2 and
diffusion-weighted sequences were used to delineate the
boost volume in all cases) and with reference to the sites
of highest Gleason score described on pathology. The
volume outlined formed the boost target volume.
The prostate and proximal seminal vesicles were
outlined to form the CTV. Normal structures were de-
lineated as per institutional protocol including delinea-
tion of the rectum as a solid structure extending from
the anus to the recto-sigmoid flexure, and delineation of
the bladder as a solid structure from bladder base to
dome.
Margins
Our institutional margins for prostate SBRT using
Cyberknife are 5 mm except 3 mm posteriorly. This is
based on the literature on prostate SBRT [11,12] and is
concordant with those used in the current randomized
PACE trial comparing SBRT with IMRT [18]. This mar-
gin is likely to account for subclinical extra-prostatic
extension [19,20] and treatment delivery uncertainties.
The prostate and seminal vesicles CTV was therefore
expanded by 5 mm isotropically except 3 mm posteriorly
to form the PTV(prostate) for the Cyberknife plans.For the RapidArc plans (which used RapidArc version
8.6), to provide pure dosimetric comparison, the first
plan used the same margins (5 mm/3 mm posteriorly) as
we would use with Cyberknife to form the PTV(pros-
tate). However, it is established that intrafraction motion
during conventional fractionation requires a margin of
2-3 mm [21-24]. Therefore a second plan was con-
structed with PTV (prostate) margins of 8 mm/5 mm
posteriorly which is likely to be sufficient to account for
intra-fraction motion after set-up to gold fiducial markers
before treatment.
No PTV margin was put around the boost region
which was always entirely contained within the prostate
CTV. Whilst a 0 mm margin for treatment delivery
accuracy is unlikely to be achievable, as the area sur-
rounding the boost was within the CTV prostate, the
dose fall off around the boost was relatively slow, and
we noted that in most cases at 2 mm from the boost,
the mean dose was maintained above 47 Gy. The boost
volume (with no margin) is hereafter called PTV (boost).
Dose
Dose to the PTV(prostate) was 36.25 Gy in 5 fractions
and dose to the PTV(boost) was 47.5 Gy. Dose schema
is shown in Figure 1.
Plans for both RapidArc and Multiplan were normal-
ized so that ≥95% of the target volume received 100% of
the dose. The organ at risk (OAR) constraints were
based on those currently used clinically at our institution
(see Table 1) for prostate SBRT.
This planning study assumed that for Cyberknife plans
treatment would be theoretically delivered with gold
fiducial intra-fraction monitoring every 30–60 seconds.
For RapidArc plans, it was assumed that patients would
be set-up to gold fiducials prior to treatment.
Statistics were calculated using Prism version 6
(GraphPad software inc). Differences between planning
methods were compared using a Wilcoxon matched-
pairs signed rank test, as a Gaussian distribution could
not be assumed and the correlation between 1 cc dose
and various parameters (PTV overlap with rectum, dis-
tance from boost to rectum, PTV volume) was explored
using linear regression.
Table 1 Dose constraints for prostate SBRT planning
Rectum Bladder
D50 D20 D10 D5 Hottest 1 cc D40 D10 Hottest 10 cc
Constraint (Gy) 18.1 29.0 32.6 36.25 37.3 (aim <36) 18.1 36.25 37.0
Figure 2 Mean rectal DVH data by planning method.
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Plan demographics
Patients had a mean age of 72, with a mean PSA of 19.1
and a mean prostate volume of 57.4 cc. Seven patients
had T3a disease and the remainder had T2a-T2c. Due to
the time, and in 13/15 cases the use of hormonal therapy
between the diagnostic MR and the planning CT scan,
and the inherent differences in CT and MR prostate out-
lining there was often significant change between the
two scans which made fusion sub-optimal. In these
cases, the prostate contour on the side of the boost was
prioritized so that the boost region remained in a repre-
sentative position. The boost was in the left lateral pos-
ition in 6 cases, the right lateral position in 5 cases, was
centrally positioned in 2 cases and was centrally posterior
in 1 case. The mean boost volume was 3.7 cc and the
mean distance from the boost to the anterior rectal wall
was 2.3 mm. The mean overlap between the PTV (5 mm/
3 mm margin) and the rectum was 2 cc (range 0.02-4.26).
For Cyberknife plans the mean number of beams was
215 and the mean number of nodes was 59. The mean
predicted treatment time was 46 minutes and the mean
conformality index for the Cyberknife plans was 1.14.
For RapidArc, the plans were constructed with a double
arc, and took at mean of 5.9 minutes to deliver and had
a mean conformality index of 1.04 (smaller margins) and
1.03 (larger margins). The median boost dose was
47.5 Gy for both planning methods but the mean D95
PTV(boost) was higher for Cyberknife (48.1 Gy) than
RapidArc (47.4 Gy) and RapidArc with larger margins
(46.9 Gy).
Rectal doses
For the same margins, the mean doses to the rectum
were higher on average for Multiplan (Figure 2 and
Table 2) which may be partly a reflection of the way in
which the optimization is driven in each system (e.g. we
have found that with Version 8.6 of RapidArc the
optimization is best if the OAR objectives are set much
lower than the actual constraints, whereas with
Multiplan over-reaching the possible OAR constraints
can result in the degradation of the plan). In contrast,
the number of constraints achieved vs failed was identi-
cal for Multiplan vs RapidArc with the same margins
(see Figure 3). However for most cases where the con-
straint was failed, it was largely by less than 1 Gy. For
example for the 12 plans which could not meet the D10
constraint of 32.6 Gy, 8 of achieved a D10 of 33.6 Gy i.e.only a 1 Gy relaxation of the constraint was needed for
most plans to accomplish this. The constraint which was
exceeded to the greatest extent was the rectal 1 cc dose
(i.e. dose to the hottest 1 cc of rectum), which was in
four cases > 2 Gy higher than the constraint (2 Rapid
Arc plans, 2 Cyberknife plans).
If the RapidArc margins were increased to 8 mm/
5 mm posteriorly then 43/75 rectal constraints were
missed. For example, the mean rectal D5 was 36.6 Gy
for these plans (which is above the constraint of
36.2 Gy) and the mean rectal 1 cc was 37.7 Gy, (max-
imum constraint 37.3 Gy).
Bladder doses
For the bladder constraints, Cyberknife plans had higher
mean values for the D40, D10 and hottest 1 cc com-
pared to the RapidArc plans with the same margins. For
example the mean dose to the hottest 10 cc was
34.97 Gy for RapidArc and 35.88 Gy for Cyberknife.
However, both of these are well within the constraint of
37 Gy (see Figure 4) and the number of missed con-
straints was similar.
The RapidArc plans with the larger margin gave more
dose to all bladder constraints tested but they still met
most constraints except the average dose to the hottest
10 cc of bladder which was 37.21 Gy, just outside the
constraint. The association of bladder dose and genito-
urinary toxicity has not been well established with con-
ventional fractionation and the implication of these dose
differences in SBRT is not known.
Are there factors which make focal dose escalation easier?
As the constraint to the hottest 1 cc of rectum was the
hardest to meet, we examined whether certain factors
are predictive of the value of this constraint. We investi-
gated whether the extent of overlap between the PTV
Table 2 Rectal dose comparison (figures in bold have exceeded the constraint)
Rectal dose Margins D50 D20 D10 D5 Hottest 1 cc
Multiplan 5 mm/3 mm post 15.52 27.13 32.40 35.32 37.15
RapidArc 5 mm/3 mm post 13.17* (p = 0.01) 24.37* (p = 0.005) 30.86 34.29 36.78
RapidArc larger margins 8 mm/5 mm post 14.59 28.28 34.61* (p = 0.001) 36.63* (p = 0.0003) 37.7
*denotes those that are significantly different from Cyberknife plans (using a paired t-test, p values in brackets).
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anterior rectal wall affected the ability to meet the most
difficult constraint, the 1 cc rectum dose.
Surprisingly, neither of these factors are clearly corre-
lated with the dose to the 1 cc rectum, except for the re-
lationship between the Rectum-PTV overlap and the
results of the RapidArc plans (p = 0.025). However this
relationship loses statistical significance if the outlier (at
16 mm) is removed.
We also examined for any correlation between dose to
the hottest 1 cc of the rectum and anterior-posterior,
left-right patient separations at the level of the prostate
and with prostate volume. No significant relationships
were found.
Discussion
Many planning studies have compared the ability of dif-
ferent planning systems to deliver SBRT. This study
compares the ability of Cyberknife and RapidArc to
achieve an intentionally heterogeneous dose distribution
and thereby achieve a differential dose to two PTVs de-
pending on risk of disease recurrence.
There are many logical reasons why dose-escalating
the dominant tumour nodule may improve the thera-
peutic ratio. However this strategy relies on being able
to delineate the dominant prostate disease nodule accur-
ately. Newer MRI techniques have improved tumour de-
lineation in prostate cancer [25-27].
In the detection of patients with prostate cancer, com-
bined dynamic contrast-enhanced (DCE) or diffusion
weighted (DWI) MRI detects a cancer-containing region
of the prostate with a high sensitivity and specificity.Figure 3 Number of missed rectal constraints by dose (43/75 for
RapidArc larger margins, 11/75 for RapidArc standard margins,
11/75 for Cyberknife standard margins).Studies have reported sensitivities of 38-82% and speci-
ficities of 37–96% for DCE or DWI alone [25,26,28-30].
The combination of both DCE-MRI and DWI further
improves delineation of tumour within the prostate [31-33].
The combination of DCE-MRI and MR-spectroscopy
(MRS) may also improve tumour delineation [34]. It ap-
pears however that maximal tumour definition requires
only 2 of the 3 modalities (DW-MRI, DCE-MRI and
MRS), and that using all 3 does not improve prostate can-
cer detection [30].
Models which use MRI parameters (including DWI
and DCE) on a voxel-by-voxel basis have been shown to
be highly reliable for predicting tumour presence on
pathology and suggested to be suitable for focal boost
therapy [35]. The conspicuity of tumour nodules has
been found to decrease in patients who have completed
more than 3 months of androgen deprivation therapy
(ADT) [36] and so it may be best to use a pre-ADT MRI
to plan a focal boost, although the change in prostate
size and shape over time may limit the accuracy of sub-
sequent fusion to a radiotherapy planning CT. 18-F
Choline-PET and Carbon-11 acetate PET have also been
used to define a radiotherapy boost volume in planning
studies [37,38].
Studies have attempted to model the extent of focal
dose escalation feasible with conventional fractionation.
Housri et al. [39] identified DPDNs in 24/42 men stud-
ied. In these men dose escalation to 151 Gy was possible
in half the cases, and was more likely to be possible in
those with a larger distance between the dominant nod-
ule and the rectum, and in those with a smaller hip-to-
hip distance on planning CT. This echoes our previously
presented work, showing that DPDN within 1.5 mm of
the rectum are more difficult to dose escalate [40].Figure 4 Mean bladder DVH data by planning method.
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relate with rectal 1 cc dose, except for a finding of bor-
derline significance for RapidArc plans. It may be that
the ability to dose escalate to 47.5 Gy is correlated with
distance to rectum, but that the dose to the 1 cc rectum
has other more complicated determinants, including
possibly a combined effect of the size of the PTV, blad-
der and rectum and size of the patient.
Both RapidArc and Multiplan are complex planning
tools and the quality of a plan is likely to be dependent
on the experience of the user. Whilst the plans in this
paper represent the best plans our department could
produce at the time, we have had longer experience with
RapidArc and hence our Cyberknife plans may still re-
flect the steep gradient of our learning curve.
It may also be that with further experience we have
learnt to improve the dose fall-off of our plans, facilitat-
ing high intraprostatic doses with less penalty in rectal
dose constraints. In addition, this is a sample of 15 pa-
tients, and larger numbers may be needed to see signifi-
cant correlations.
The two systems discussed here have markedly differ-
ent treatment times. The rate at which dose is delivered
is likely to have some implication however the size and
direction of this influence is complex [41] and likely to
have a differential effect depending on a/b ratio of the
tissue in question. The oncological and side effect impli-
cations of a 40 minute vs a 6 minute treatment time, if
any, are yet to be ascertained in vivo.
Both Multiplan and RapidArc planning systems can
produce clinically acceptable plans which deliver a focal
boost of 47.5 Gy in 5 fractions whilst treating the entire
prostate to 36.25 Gy. The extent of focal dose escalation
possible without unacceptable OAR dose penalty may
seem surprising but the use of either many beams, or
arcing beams facilitates a rapid dose fall-off. The
Cyberknife system incorporates near real-time tracking
of the prostate which allows smaller margins to be used,
such as those used in this study, as it tracks and corrects
for intra-fraction motion. This paper suggests that if
intra-fraction motion could be tracked and corrected
during arc-therapy on a conventional linac, then the
dosimetry is likely to be at least as good as Cyberknife.
However, without intra-fraction motion control, a mar-
gin of 2–3 mm is likely to be needed to account for
intrafraction motion after initial set-up to gold markers
[42] which in this study is associated with exceeding
dose constraints around half of the time. Alternatively, if
new flattening-free filter linacs can deliver these plans in
much shorter times, then intra-fraction motion may be
less important, although transient, significant excursions
of prostate position are still possible [43].
The optimization algorithms for RapidArc and Multiplan
are different and, at least in our hands, these differencesresult in a slightly lower mean dose for RapidArc com-
pared to Multiplan. In further work, not shown here, we
have found that Multiplan can produce similar DVH
values to RapidArc on individual plans, once the lowest
achievable levels have been established with a RapidArc
plan. It may be that further improvement in the Multiplan
plans is possible as we gain further experience with this
technique or as the optimization algorithm evolves.
We have established that it is possible to focally dose
escalate prostate SBRT to target the dominant lesion.
The next step is to establish if this can be achieved in
patients without significant increase in toxicity, and
whether focal dose escalation translates into improved
biochemical control. This is being tested with conven-
tional fractionation in the FLAME trial [44] which is
currently randomizing patients (single-blind) to standard
radiotherapy (77 Gy in 35 fractions) or the same dose
plus a simultaneous integrated boost to the dominant
nodule to 95 Gy. This trial is defining the boost volume
using MRI, including DCE- and DWI-MRI. The primary
end-point is biochemical relapse-free survival at 5-years.
Previous non-randomised studies have shown that mod-
erate boosting to the dominant nodule (80–82 Gy) with
conventional fractionation can be achieved without in-
crease in toxicity [45-48].
The margins needed for an intra-prostatic boost are
not well defined. Some studies have used 2-4 mm mar-
gins [45,47,49] whereas others have not used an intra-
prostatic PTV margin [46]. As the boost is within the
PTV (prostate) the dose fall-off is likely to be shallow
enough to significantly dose-escalate 2-3 mm away from
the delineated DPDN.
We have designed a pilot study of focal boosting using
5 fractions of SBRT, based on the planning technique
used for this study. The SPARC trial (Stereotactic pros-
tate augmented radiotherapy with Cyberknife) aims to
establish if focal doses up to 47.5 Gy in 5 fractions (and
36.25 Gy in 5 fractions to the whole prostate) can be de-
livered to patients with intermediate and high risk pros-
tate cancer without significant increase in acute toxicity.
Conclusion
The ability to utilize non-coplanar, non-isocentric beams
did not significantly improve focal boost plans compared
to arc therapy. Rapid Arc plans delivered lower mean
rectal doses, but both systems achieved the dose con-
straints in the same number of cases. However, without
the ability to track intrafraction motion the PTV would
have to be increased by a further 2-3 mm, particularly as
the plans take an average of 5.9 minutes to deliver. If the
PTV margin is increased to this extent, plans no longer
meet the constraints in many cases. Intra-fraction mo-
tion monitoring facilitates the smaller margins needed to
deliver a simultaneous integrated boost to the dominant
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nique clinically in a pilot study to assess whether these
SIB plans can be delivered clinically without additional
toxicity.
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